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We read with interest the recently published article
by Hodgson et al.1 reporting a lack of association
between idiopathic pulmonary fibrosis and the
complement receptor 1 (CR1) gene C5507G poly-
morphism among a series of Finnish patients. This
evidence contrasts with our research group’s pre-
vious report,2 showing an association between
polymorphisms and this disease in an Italian series
of patients. Moreover, based on their results,
Dr. Hodgson and coworkers stated that the CR1
G5507 is not a polymorphic site in the Finnish, since
the C allele was never found, either among patients
or among controls. Since we noticed that
Dr. Hodgson and coworkers used a markedly differ-
ent methodology than that described by Zorzetto
et al.2 we decided to conduct a comparative
experiment.
To this aim, we investigated six individuals
already assessed for the CR1 C5507G by sequen-
cing. We used three pairs of primers: Zorzetto F
and R, Hodgson 1 F and R and Hodgson 2 F and R:
(Table 1), and two restriction enzymes: MnlI and
HpyCH4III, showing altered restriction sites for the
C5507G polymorphism. PCR fragments amplified
with Zorzetto and Hodgson 1 primers, were
digested with the MnlI and HpyCH4III enzymes,
while PCR fragments amplified with Hodgson 2
primers was digested only with MnlI. Figs. 1A and B
illustrate the digestion of the amplimers obtained
with Zorzetto primers, with MnlI and HpyCH4III,
respectively; Figs. 1C and D show the digestion of
amplimers obtained with Hodgson primers 1 and
digested with MnlI and HpyCH4III, respectively.
Fig. 1E shows the digestion of amplimers obtained
with Hodgson primers 2 and digested with MnlI. The
figure clearly shows that amplification of the six
samples with Zorzetto primers, followed by diges-
tion with either MnlI (Fig 1A) or HpyCH4III (Fig 1B),
differentiates the three genotypes determined by
the C5507G polymorphism. In contrast, amplifica-
tion of the same samples with Hodgson 1 and 2
primers, followed by the digestion with MnlI (Fig 1C
and E) or HpyCH4III (Fig 1D) was not able toee front matter & 2005 Elsevier Ltd. All rights reserv
med.2005.07.009discriminate the three genotypes determined by
the polymorphism.
Further to this, we aligned the sequences of the
three pairs of primers with a sequence (AL137789.11)
on chromosome 1 containing the CR1 gene. The blast
result of our primers with sequence AL137789.11
shows a unique possible amplimer in our PCR
conditions (F: 44674444694 and R: 44978444957).
We well know that the R primer also recognizes the
AL137789.11 sequence from 13052 to 13031, but the
putative PCR product is too long to be amplified by
Taq Polymerase in these conditions.
The first pair of primers described in Hodgson’s
paper (Hodgson1) aligned with a AL137789.11
sequence (F: 4476144470 or 12835412854 and
R: 13162413137) does not amplify the same
sequence of our primers, therefore with this pair
of primers it is not possible to amplify the region
containing the C5507G polymorphism.
When we aligned the second pair of Hodgson
primers with sequence AL137789.11, we found at
least two different possible PCR fragments of the
CR1 gene (F: 44882444901 or 12956412975 and R:
44956444940 or 13030413014). Only one of these
contains the C5507G polymorphic site, thus, using
this couple, amplification of only the region of
interested is not guaranteed.
The human CR1 molecule is a large transmem-
brane glycoprotein that is encoded in a cluster on
chromosome 1q32 together with genes for five
other closely related C3b/C4b-binding proteins,
known together as the regulators of complement
activation (RCA). The RCA proteins are structurally
similar in that they are predominantly composed of
repeated motifs of approximately 60–70 amino
acids, termed short consensus repeats (SCRs), or
complement control protein repeats (CCPs). Each
SCR has a number of highly conserved residues in
common, including four invariant cysteines that
form two disulfide bonds. These characteristics of
the CR1 gene cause problems for anyone trying to
design primers for this region. In fact a pair of
primers could recognize various regions inside the
CR1 that could be amplified along with the region
of interest.ed.
ARTICLE IN PRESS
Table 1 Sequence of primers and restriction fragments for the detection of CR1 C5507G polymorphisms.
Primers Size Enzyme Fragment
Zorzetto F: 50-AAGCGCACAGTCACAGGTCAC-30 305 MnlI C: 111, 80, 37, 33, 33, 11
R: 50-GAACAGAAAGTTCACAGCGAGG-30 G: 111, 80, 70, 33, 11
Zorzetto F: 50-AAGCGCACAGTCACAGGTCAC-30 305 HpyCH4III C: 296, 9
R:50- GAACAGAAAGTTCACAGCGAGG-30 G: 242, 54, 9
Hodgson 1 F: 50-CTTTTGTCCAAATCCTCCAG-30 328 HpyCH4III C: 328
R: 50-AAAGTTAAGCTCACAAACAAATACCA-30 G: 164, 164
Hodgson 1 F: 50-CTTTTGTCCAAATCCTCCAG-30 328 MnlI C: 82,43,38,37,37,33,33,24
R: 50-AAAGTTAAGCTCACAAACAAATACCA-30 G: 82,70,43,38,37,33,24
Hodgson 2 F: 50-TTCAACCTCATTGGGGAGAG-30 74 MnlI C: 37, 29, 9
R: 50-GGCAGGGCTGCTCCAAA-30 G: 66, 9
Figure 1 (A) and (B) show the digestion of the amplimers obtained with our primers, with MnII and HpyCH4III,
respectively; (C) and (D) show the digestion of Hodgson 1 amplimers with MnII and HpyCH4III, respectively; (E) shows
the digestion of Hodgson 2 amplimers with MnII. M ¼ 100 bp marker.
LETTER TO THE EDITOR 187Given the unique genetic make-up of the Finnish
population, due to its genetic isolation, we cannot
exclude that the CR1 G5507 might indeed be a
monomorphic site in the Finnish, despite being
polymorphic in the other populations investigated,
but we would like to emphasize that the conclusions
drawn by Dr. Hodgson are dependent on the investi-
gative methodology used, which could be flawed.References
1. Hodgson U, Tukiainen P, Laitinen T. The polymorphism C5507G
of complement receptor 1 does not explain idiopathicpulmonary fibrosis among the Finns. Respir Med 2005;
99:265–7.
2. Zorzetto M, Ferrarotti I, Trisolini R, et al. Complement
receptor 1 gene polymorphisms are associated with idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:
330–4.Michele Zorzetto, Ilaria Ferrarotti, Ilaria Campo,
Maurizio Luisetti
Laboratorio di Biochimica e Genetica, Clinica di
Malattie dell’Apparato Respiratorio, IRCCS
Policlinico San Matteo, Universita` di Pavia, Italy
E-mail address: m.zorzetto@smatteo.pv.it
(M. Zorzetto)
